Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
dc.contributor.author | Farren, TW | en_US |
dc.contributor.author | Giustiniani, J | en_US |
dc.contributor.author | Fanous, M | en_US |
dc.contributor.author | Liu, F | en_US |
dc.contributor.author | Macey, MG | en_US |
dc.contributor.author | Wright, F | en_US |
dc.contributor.author | Prentice, A | en_US |
dc.contributor.author | Nathwani, A | en_US |
dc.contributor.author | Agrawal, SG | en_US |
dc.date.accessioned | 2015-05-12T14:36:08Z | |
dc.date.available | 2014-10-29 | en_US |
dc.date.issued | 2015-01 | en_US |
dc.identifier.issn | 2044-5385 | en_US |
dc.identifier.other | ARTN e273 | en_US |
dc.identifier.other | ARTN e273 | en_US |
dc.identifier.other | ARTN e273 | en_US |
dc.identifier.uri | http://www.nature.com/bcj/journal/v5/n1/full/bcj201492a.html | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/7439 | |
dc.language.iso | en | en_US |
dc.relation.ispartof | BLOOD CANCER JOURNAL | en_US |
dc.title | Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1038/bcj.2014.92 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348988100002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 5 | en_US |
Files in this item
This item appears in the following Collection(s)
-
Centre for Immunobiology [1122]